Biofoundry-as-a-service market set to double by 2030

By AI, Created 5:19 PM UTC, May 18, 2026, /AGP/ – The biofoundry-as-a-service market is projected to grow from $1.65 billion in 2025 to $4.38 billion by 2030, driven by automation, AI tools and rising life sciences investment. North America led the market in 2025, while Asia-Pacific is expected to post the fastest growth.

Why it matters: - Biofoundry-as-a-service gives researchers remote access to automated biological engineering facilities, lowering the need for expensive in-house infrastructure. - The model can speed up synthetic biology, genetic engineering and R&D workflows for biotech, pharma and academic users. - Strong projected growth signals rising demand for outsourced, high-throughput bioengineering capacity.

What happened: - The biofoundry-as-a-service market is projected to rise from $1.65 billion in 2025 to $2.01 billion in 2026. - The market is forecast to reach $4.38 billion by 2030. - The projected CAGR is 21.3% from 2025 to 2026 and 21.6% through 2030. - The Business Research Company said the forecast reflects rapid adoption of automated lab tools and broader use of AI-based biofoundry platforms. - Download a free sample of the biofoundry-as-a-service market report.

The details: - Biofoundry-as-a-service combines robotics, advanced software and data analytics to design, build and test genetic constructs and organisms. - The service model lets users access high-throughput biological engineering facilities through digital or remote interfaces. - Growth over the historical period was driven by funding in synthetic biology, automated lab equipment, genetic engineering demand, academic and research expansion and more biotechnology firms. - Future growth is expected to come from cloud-enabled design-build-test-learn services, integrated bioengineering offerings and expanded pharmaceutical and industrial biotechnology use. - Key forecast trends include automated DNA assembly services, machine learning inside biofoundries and platform-as-a-service bioengineering offerings. - Rising investment in life sciences is a major driver because it supports healthcare, biotechnology, pharmaceuticals, medical devices and biological innovation. - Government and institutional funding is also helping market growth. - In September 2025, the UK government pledged up to $707 million (£520 million) in capital grants to attract investment in innovative life sciences manufacturing. - The Association of the British Pharmaceutical Industry highlighted the UK funding move as support for the country’s position as a global life sciences hub. - View the full biofoundry-as-a-service market report. - North America led the market in 2025. - Asia-Pacific is expected to grow the fastest over the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The market outlook points to a shift from specialized lab infrastructure toward service-based access to biological engineering. - AI, cloud software and machine learning are becoming central to biofoundry operations, not just add-ons. - Public funding and private investment appear to be reinforcing each other as the sector scales.

What’s next: - Biofoundry providers are likely to expand automated DNA assembly and integrated DBTL offerings. - Regional growth should broaden beyond North America as Asia-Pacific demand accelerates. - More life sciences manufacturers and research groups may adopt remote bioengineering services as tooling improves and costs fall. - Browse related market reports including strategy advisory and classroom management systems.

The bottom line: - Biofoundry-as-a-service is moving from a niche research model to a fast-growing market built on automation, AI and outsourced biotech infrastructure.